Rimonabant was authorized in Europe in 2006 as an anti-obesity medication and then withdrawn by the European Medicines Agency (EMA) in 2009 leading to the termination of the development of other cannabinoid receptor 1 (CB1) blockers for obesity [21, 22]. Here, CNR1 is linked to obesity disorder.